Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (
NYSE: AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for open surgical repair. The purchase price for the acquisition is $175M less offsets for previously provided loans, plus a potential for up to $200M in additional consideration contingent upon U.S. NEXUS commercial performance over the next two years.
